[HTML][HTML] CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
L Chen, B Xu, X Long, J Gu, Y Lou… - … for Immunotherapy of …, 2020 - ncbi.nlm.nih.gov
L Chen, B Xu, X Long, J Gu, Y Lou, D Wang, Y Cao, N Wang, C Li, G Wang, Y Wang, L Zhu…
Journal for Immunotherapy of Cancer, 2020•ncbi.nlm.nih.govBackground Li-Fraumeni syndrome (LFS) is characterized as an autosomal dominant
cancer predisposition disorder caused by germline TP53 gene mutations. Both primary and
therapy-related hematopoietic malignancies with LFS are associated with dismal outcomes
with standard therapies and even allogenic stem cell transplantation (SCT).
cancer predisposition disorder caused by germline TP53 gene mutations. Both primary and
therapy-related hematopoietic malignancies with LFS are associated with dismal outcomes
with standard therapies and even allogenic stem cell transplantation (SCT).
Abstract
Background
Li-Fraumeni syndrome (LFS) is characterized as an autosomal dominant cancer predisposition disorder caused by germline TP53 gene mutations. Both primary and therapy-related hematopoietic malignancies with LFS are associated with dismal outcomes with standard therapies and even allogenic stem cell transplantation (SCT).
ncbi.nlm.nih.gov
